Results 151 to 160 of about 1,585,176 (291)

Classification of Odontogenic Sinusitis: A Clinical-Based Phenotyping System to Guide Multidisciplinary Surgical Management. [PDF]

open access: yesLaryngoscope Investig Otolaryngol
Sabatino L   +8 more
europepmc   +1 more source

Outcomes of adalimumab biosimilar nonmedical switches in children and young adults with inflammatory bowel disease

open access: yesJPGN Reports, EarlyView.
Abstract Objectives Adalimumab biosimilars are as safe and effective compared to the originator. Adult patients with inflammatory bowel disease (IBD) who switched to a biosimilar have comparable outcomes, but pediatric data are limited. This study evaluates clinical outcomes of children and young adults with IBD following a nonmedical, insurance‐driven
Daniel Himelstein   +5 more
wiley   +1 more source

Diffuse gallbladder epithelial proliferation after teduglutide exposure: A case report

open access: yesJPGN Reports, EarlyView.
Abstract Teduglutide, a glucagon‐like peptide 2 analog that increases mucosal proliferation in the gastrointestinal tract, was approved by the U.S. Food and Drug Administration for use in children with intestinal failure in 2019 after trials of 12‐ and 24‐week duration.
Christopher P. Duggan   +4 more
wiley   +1 more source

Beyond the gut: Non‐specific interstitial pneumonia in pediatric ulcerative colitis—A rare extra‐intestinal manifestation

open access: yesJPGN Reports, EarlyView.
Abstract Inflammatory bowel disease (IBD) is a chronic inflammatory disorder often presenting with extra‐intestinal manifestations (EIMs) involving the skin, joints and eyes. However, pulmonary manifestation, such as interstitial lung disease (ILD), is a rare complication, particularly in the pediatric population. We report a case of a 10‐year‐old boy,
Harshit Vachher   +5 more
wiley   +1 more source

Long‐Term Clinical Response After Low‐Dose and Short‐Duration Cemiplimab Therapy in a Patient With Xeroderma Pigmentosum in Nepal

open access: yesJEADV Clinical Practice, EarlyView.
Capsule Summary Xeroderma pigmentosum (XP) is associated with a high risk of multiple and aggressive cutaneous squamous cell carcinomas (CSCCs). The immune checkpoint inhibitor cemiplimab has been approved in advanced, unresectable, and/or metastatic CSCCs.
Sudip Parajuli   +5 more
wiley   +1 more source

Microvascular Free Flap Transfer for the Closure of Recalcitrant Digestive Fistulas: A Systematic Review of Surgical Success, Definitive Closure, and Clinical Outcomes. [PDF]

open access: yesCureus
Vega Morales AQ   +8 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy